Healthcare Stocks Surge as Tech Stumbles: Is the Defensive Rotation Just Getting Started?

If you blinked, you missed the moment tech’s grip on the market slipped. The so-called “Magnificent 7” have finally started to look mortal, and the money that once chased every AI-fueled whisper in Silicon Valley is now stampeding into healthcare. The rotation isn’t subtle. Shares of AbbVie, Eli Lilly, and Johnson & Johnson are flirting with all-time highs while the NASDAQ’s tech darlings are getting unceremoniously dumped. The market’s breadth has actually improved as tech falters, a rare sight in a decade defined by narrow leadership. If you’re still clinging to the idea that the only way to outperform is to own the next Nvidia, you’re missing the real story: the risk-on crowd is quietly turning risk-off, and the tape is rewarding old-school defensives.

Let’s get granular. The Investment Committee’s latest televised debate (YouTube, June 26) was less about how to buy the dip in tech and more about how to avoid getting run over by it. The numbers back up the angst. XLK, the tech sector ETF, is frozen at $184.83, showing zero movement as the rest of the market churns. Meanwhile, the healthcare sector is on a tear, with big pharma names notching new highs. MarketWatch reports (June 26) that investors are treating healthcare as a haven, a phrase that hasn’t been uttered with a straight face since the pandemic. The rotation is happening while the S&P’s advance/decline line turns positive, even as tech wobbles. Barron’s (June 26) points out that market breadth is widening, a classic sign that the generals are falling but the troops are still marching.

The macro backdrop is adding fuel to the fire. The Fed isn’t expected to raise rates this year, according to EY-Parthenon’s Greg Daco (CNBC, June 26), and the market is pricing in a soft landing. But the real driver is positioning. After a year of crowding into tech, funds are de-grossing and reallocating to sectors with actual cash flow and pricing power. Healthcare fits the bill. The sector’s defensive characteristics, inelastic demand, fat margins, and regulatory moats, are suddenly back in vogue. It’s a classic late-cycle play, but this time the cycle is being driven as much by AI fatigue as by macro risk.

The historical parallels are hard to ignore. The last time we saw a rotation of this magnitude was in 2016, when the Trump trade pushed money out of FANG and into banks and industrials. This time, it’s not about reflation or deregulation. It’s about survival. With tech valuations stretched and earnings momentum stalling, the path of least resistance is toward sectors that can weather a slowdown. Healthcare’s outperformance isn’t just a defensive reflex. It’s a bet that the next leg of the bull market will be led by companies that don’t need a new AI model every quarter to justify their multiples.

The cross-asset signals are flashing caution. Commodities are flatlining, DBC is stuck at $28.55, unmoved by oil’s latest drama in the Strait of Hormuz. The bond market is eerily calm, with yields drifting lower as recession chatter fades. The only real volatility is in tech, where options skew is blowing out and implied vols are creeping higher. The rest of the market is quietly grinding higher, led by sectors that haven’t mattered in years.

The absurdity is palpable. For months, the narrative was that you had to own tech or be left behind. Now, the same desks that were pounding the table on AI are scrambling to explain why they’re overweight pharma. The real story is that the market is finally rewarding diversification. The risk isn’t missing the next big thing. It’s being the last one out of the old one.

Strykr Watch

The technicals are lining up for a sustained move in healthcare. XLV, the healthcare ETF, is breaking out of a multi-month base, with RSI climbing above 65 and MACD turning positive. Key support sits at the 50-day moving average, with resistance at the previous all-time high. Pharma names like Eli Lilly and Johnson & Johnson are posting bullish engulfing candles on the daily chart, a sign that institutional money is flowing in. The rotation out of tech is being confirmed by relative strength charts, XLV/XLK ratio is at a two-year high. Watch for continued outperformance as long as tech remains under pressure.

The risk is that this is just a dead-cat bounce in defensives, but the breadth and volume suggest otherwise. The tape is telling you to respect the move. If you’re looking for confirmation, watch the next earnings cycle. If healthcare can deliver on expectations while tech disappoints, the rotation has legs.

The bear case is that a Fed pivot or a tech earnings surprise could reverse the flow overnight. But with positioning still lopsided and sentiment stretched, the path of least resistance is higher for healthcare.

The opportunity is clear. Long healthcare on dips, with stops just below the 50-day moving average. Fade tech rallies until the sector proves it can reclaim leadership. The risk/reward favors defensives as long as macro volatility stays contained.

Strykr Take

The market has finally remembered that there’s more to life than tech. The rotation into healthcare isn’t a fluke. It’s a structural shift driven by positioning, valuation, and the simple fact that not every company needs to invent the next big thing to make money. If you’re still chasing the AI trade, you’re playing last year’s game. The smart money is already moving on.

datePublished: 2026-06-26